Evidence map›Paper›PMID 41431418›Full record

Observational studyThoracic cancer2025

Peripheral Immune Cell Profiles as Predictive Biomarkers of Immune Checkpoint Inhibitor Efficacy in Elderly Patients With Advanced Non-Small Cell Lung Cancer.

Shouzheng Wang, Yilin Wang, Xi Li, Quan Zhang, Jialin Lv, Yu Pang, Ying Hu

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shouzheng WangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID https://orcid.org/0000-0003-3697-4643
Yilin WangDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Xi LiDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Quan ZhangDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Jialin LvDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yu PangDepartment of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID https://orcid.org/0000-0001-6803-9807
Ying HuDepartment of Medical Oncology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.

Funding

Beijing Hospitals Authority Innovation Studio of Young Staff Funding Support 202333Tongzhou District Health Development Research Reserve Project of Tongzhou District Commission of Science and Technology of Beijing Municipality of China KJ2023CX054
6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) significantly impact advanced non-small cell lung cancer (NSCLC) management, but predictive biomarkers for elderly patients remain controversial. This study aimed to assess peripheral immune cells as biomarkers for predicting ICI efficacy in elderly NSCLC patients.

methodsThis was an ambispective, observational study enrolling patients aged ≥ 65 years with advanced NSCLC treated with first-line ICI ± chemotherapy from January 2023 to August 2024 at Beijing Chest Hospital. Peripheral immune cell subsets were analyzed by flow cytometry at baseline and dynamically during treatment. Associations between clinical characteristics, immune cell profiles, and outcomes were assessed using Kaplan-Meier analysis, Cox regression, and Wilcoxon tests.

resultsA total of 34 patients were included in this study. Objective response rate and disease control rate were 41.2% and 97.1%, respectively. Median progression-free survival (PFS) was 10.3 months, while median overall survival (OS) was not reached. Patients responding to ICIs had significantly higher baseline percentages of CD3

conclusionsPeripheral cytotoxic T cell subsets may serve as promising biomarkers for predicting the efficacy of ICIs in elderly NSCLC patients. Dynamic monitoring of immune cell profiles could further enhance prognostic accuracy.

Indexed as

Biomarkers, TumorCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsAgedAged, 80 and overFemaleHumansMalePrognosisBiomarkers, TumorImmune Checkpoint Inhibitorsbiomarkerselderly patientsimmune checkpoint inhibitorsnon‐small cell lung cancerperipheral immune cells

Identifiers

PMID41431418
PMCPMC12723315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.